According to a report from CCX Media last week, HistoSonics plans to expand its headquarters in Plymouth, Minnesota.
HistoSonics develops a histotripsy treatment for liver tumor procedures. Last year, the FDA granted de novo authorization for its Edison system and novel histotripsy therapy platforms.
The report says HistoSonics plans to nearly double the size of its headquarters as it seeks a conditional use permit amendment from the city. It plans to move into three tenant spaces that would add about 26,000 square feet of space to its existing 26,855-square-foot lease.
CCX Media says the Plymouth Planning Commission is reviewing the expansion proposal.
